News for Spero Therapeutics, Inc. (SPRO)

Cash and Cash Equivalents: $52.9 million as of December 31, 2024.Fourth Quarter Revenue: $15 million, down from $73.5 million in Q4 2023.Full-Year Revenue: $48

Mar 27, 2025 / 08:30PM GMTOperator Good afternoon and welcome to the Spero Therapeutics fourth-quarter and full-year 2024 earnings conference call. At this time

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ( SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on iden

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ( SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused

**media[550000]**

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ( SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential. Read more to see why I rate SPRO stock a buy.

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

**media[511560]**

Esther Rajavelu named Interim President & CEO of Spero Therapeutics amid leadership changes due to SEC disclosures.

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[459669]**

Shares of Alphabet Inc. GOOGL GOOG rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results. ...

Spero Therapeutics (SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active...

In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...